Gene amplification and immunohistochemical expression of ERBB2 and EGFR in cervical carcinogenesis. Correlation with cell-cycle markers and HPV presence

Experimental and Molecular Pathology

Volumn 95, Issue 2, 2013, Pages 151-155

  Conesa Zamora, Pablo ^a   Torres Moreno, Daniel ^a   Isaac, María A ^b   Pérez Guillermo, Miguel ^b  

^a University Hospital Santa Lucia   (Spain)

^b HUGSL   (Spain)

Author keywords

Cervical cancer; EGFR; ERBB2; FISH; HER2; HPV; Ki67; P16; P53; Squamous intraepithelial lesion

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; PROTEIN P16; PROTEIN P53;

ADULT; ARTICLE; CARCINOGENESIS; CELL CYCLE; CHROMOSOME 17; CHROMOSOME 7; CONTROLLED STUDY; EGFR GENE; ERBB2 GENE; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE SQUAMOUS CERVICAL CARCINOMA; LOW GRADE SQUAMOUS INTRAEPITHELIAL LESION; MAJOR CLINICAL STUDY; NONHUMAN; POLYPLOIDY; PROTEIN EXPRESSION; UTERINE CERVIX CANCER; WART VIRUS;

CC; CERVICAL CANCER; CERVICAL CARCINOGENESIS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CIN; EGFR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERBB2; FISH; FLUORESCENCE IN SITU HYBRIDIZATION; HER2; HIGH-GRADE SQUAMOUS INTRAEPITHELIAL LESION; HPV; HPV16; HSIL; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS GENOTYPE 16; ICC; INVASIVE SQUAMOUS CERVICAL CARCINOMA; KI67; LOW-GRADE SQUAMOUS INTRAEPITHELIAL LESION; LSIL; N/B; NORMAL/BENIGN; P16; P53; SIL; SQUAMOUS INTRAEPITHELIAL LESION;

CELL CYCLE; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; GENE AMPLIFICATION; GENES, ERBB-1; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; PAPILLOMAVIRUS INFECTIONS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 84880338795     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2013.06.011     Document Type: Article

References (29)

1. Argyriou A.A., Kalofonos H.P. Recent advances relating to the clinical application of naked monoclonal antibodies in solid tumors. Molecular Medicine 2009, 15:183-191.
2. Arias-Pulido H., Joste N., Chavez A., Muller C.Y., Dai D., Smith H.O., Verschraegen C.F. Absence of epidermal growth factor receptor mutations in cervical cancer. International Journal of Gynecological Cancer 2008, 18:749-754.
3. Chapman W.B., Lorincz A.T., Willett G.D., Wright V.C., Kurman R.J. Epidermal growth factor receptor expression and the presence of human papillomavirus in cervical squamous intraepithelial lesions. International Journal of Gynecological Pathology 1992, 11:221-226.
4. Chavez-Blanco A., Perez-Sanchez V., Gonzalez-Fierro A., Vela-Chavez T., Candelaria M., Cetina L., Vidal S., Dueñas-Gonzalez A. HER2 expression in cervical cancer as a potential therapeutic target. BMC Cancer 2004, 4:59.
5. Conesa-Zamora P., Doménech-Peris A., Orantes-Casado F.J., Ortiz-Reina S., Sahuquillo-Frías L., Acosta-Ortega J., García-Solano J., Pérez-Guillermo M. Effect of human papillomavirus on cell cycle related proteins p16, Ki67, cyclin D1, p53 and ProEx C in precursor lesions of cervical carcinoma. A tissue microarray study. American Journal of Clinical Pathology 2009, 132:378-390.
6. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clinical Science 2006, 110:525-541.
7. Dueñas-Gonzalez A., Cetina L., Mariscal I., de la Garza J. Modern management of locally advanced cervical carcinoma. Cancer Treatment Reviews 2003, 29:389-399.
8. El Hamdani W., Amrani M., Attaleb M., Laantri N., Ennaji M.M., Khyatti M., El Mzibri M. EGFR, p16INK4a and E-cadherin immuno-histochemistry and EGFR point mutations analyses in invasive cervical cancer specimens from Moroccan women. Cellular and Molecular Biology (Noisy-le-Grand, France) 2010, 56:OL1373-OL1384. (Suppl.).
9. Fuchs I., Vorsteher N., Bühler H., Evers K., Sehouli J., Schaller G., Kümmel S. The prognostic significance of human epidermal growth factor receptor correlations in squamous cell cervical carcinoma. Anticancer Research 2007, 27:959-963.
10. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA: A Cancer Journal for Clinicians 2011, 61:69-90.
11. Kersemaekers A.M., Fleuren G.J., Kenter G.G., Van den Broek L.J., Uljee S.M., Hermans J., Van de Vijver M.J. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clinical Cancer Research 1999, 5:577-586.
12. Kim J.W., Kim Y.T., Kim D.K., Song C.H., Lee J.W. Expression of epidermal growth factor receptor in carcinoma of the cervix. Gynecologic Oncology 1996, 60:283-287.
13. Lesnikova I., Lidang M., Hamilton-Dutoit S., Koch J. HER2/neu (c-erbB-2) gene amplification and protein expression are rare in uterine cervical neoplasia: a tissue microarray study of 814 archival specimens. APMIS 2009, 117:737-745.
14. Mark H.F., Feldman D., Das S., Sun C.L., Samy M., Lathrop J. HER-2/neu oncogene amplification in cervical cancer studied by fluorescent in situ hybridization. Genetic Testing 1999, 3:237-242.
15. Marzano R., Corrado G., Merola R., Sbiroli C., Guadagni F., Vizza E., Del Nonno F., Carosi M., Galati M.M., Sperduti I., Cianciulli A.M. Analysis of chromosomes 3, 7, X and the EGFR gene in uterine cervical cancer progression. European Journal of Cancer 2004, 40:1624-1629.
16. Mitra A.B., Murty V.V., Pratap M., Sodhani P., Chaganti R.S. ERBB2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix. Cancer Research 1994, 54:637-639.
17. Monk B.J., Mas Lopez L., Zarba J.J., Oaknin A., Tarpin C., Termrungruanglert W., Alber J.A., Ding J., Stutts M.W., Pandite L.N. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology 2010, 28:3562-3569.
18. Moreno-Bueno G., Sánchez-Estévez C., Cassia R., Rodríguez-Perales S., Díaz-Uriarte R., Domínguez O., Hardisson D., Andujar M., Prat J., Matias-Guiu X., Cigudosa J.C., Palacios J. Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. Cancer Research 2003, 63:5697-5702.
19. Mourón S.A., Abba M.C., Güerci A., Gómez M.A., Dulout F.N., Golijow C.D. Association between activated K-ras and c-erbB-2 oncogenes with "high-risk" and "low-risk" human papilloma virus types in preinvasive cervical lesions. Mutation Research 2000, 469:127-134.
20. Ngan H.Y., Liu S.S., Yu H., Liu K.L., Cheung A.N. Proto-oncogenes and p53 protein expression in normal cervical stratified squamous epithelium and cervical intra-epithelial neoplasia. European Journal of Cancer 1999, 35:1546-1550.
21. Ngan H.Y., Cheung A.N., Liu S.S., Cheng D.K., Ng T.Y., Wong L.C. Abnormal expression of epidermal growth factor receptor and c-erbB2 in squamous cell carcinoma of the cervix: correlation with human papillomavirus and prognosis. Tumour Biology 2001, 22:176-183.
22. Pérez-Regadera J., Sánchez-Muñoz A., De-la-Cruz J., Ballestín C., Lora D., García-Martín R., Mendiola C., Alonso L., Alba E., Lanzós E. Negative prognostic impact of the coexpression of epidermal growth factor receptor and c-erbB-2 in locally advanced cervical cancer. Oncology 2009, 76:133-141.
23. Rosty C., Couturier J., Vincent-Salomon A., Genin P., Fréneaux P., Sigal-Zafrani B., Sastre-Garau X. Overexpression/amplification of HER-2/neu is uncommon in invasive carcinoma of the uterine cervix. International Journal of Gynecological Pathology 2004, 23:13-17.
24. Shen L., Shui Y., Wang X., Sheng L., Yang Z., Xue D., Wei Q. EGFR and HER2 expression in primary cervical cancers and corresponding lymph node metastases: implications for targeted radiotherapy. BMC Cancer 2008, 8:232.
25. Wells M., Östor A.G., Crum C.P., Franceschi S., Tommasino M., Nesland J.M., Goodman A.K., Sankaranarayanan R., Hanselaar A.G., Albores-Saavedra J. Tumors of the uterine cervix. Epithelial tumors. Tumours of the Breast and Female Genital Organs 2003, 262-279. WHO, IARC Press, Lyon. F.A. Tavassoli, P. Devilee (Eds.).
26. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., Dowsett M., Fitzgibbons P.L., Hanna W.M., Langer A., McShane L.M., Paik S., Pegram M.D., Perez E.A., Press M.F., Rhodes A., Sturgeon C., Taube S.E., Tubbs R., Vance G.H., van de Vijver M., Wheeler T.M., Hayes D.F. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Archives of Pathology & Laboratory Medicine 2007, 131:18-43.
27. Yamashita H., Murakami N., Asari T., Okuma K., Ohtomo K., Nakagawa K. Correlation among six biologic factors (p53, p21(WAF1), MIB-1, EGFR, HER2, and Bcl-2) and clinical outcomes after curative chemoradiation therapy in squamous cell cervical cancer. International Journal of Radiation Oncology, Biology, and Physics 2009, 74:1165-1172.
28. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nature Reviews Molecular Cell Biology 2001, 2:127-137.
29. Zhang A., Månér S., Betz R., Angström T., Stendahl U., Bergman F., Zetterberg A., Wallin K.L. Genetic alterations in cervical carcinomas: frequent low-level amplifications of oncogenes are associated with human papillomavirus infection. International Journal of Cancer 2002, 101:427-433.